Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Détails
ID Serval
serval:BIB_D9A844DF0406
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Périodique
Lancet
ISSN
0140-6736 (Print)
Statut éditorial
Publié
Date de publication
03/1999
Volume
353
Numéro
9156
Pages
863-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Mar 13
Research Support, Non-U.S. Gov't --- Old month value: Mar 13
Résumé
BACKGROUND: The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice. METHODS: We analysed prospective data from the Swiss HIV Cohort Study on suppression of viral load and progression to AIDS or death in 2674 outpatients (median age 36 years, 27.3% women) who started HAART in 1995-98. Viral rebound was defined as two consecutive HIV-1-RNA measurements of more than 400 copies/mL. We analysed separately outcomes in patients with a history of antiretroviral treatment and in treatment-naive patients. FINDINGS: An estimated 90.7% of treatment-naive patients reached undetectable viral load (<400 copies/mL) by 12 months. Among pretreated patients, estimates ranged from 70.3% treated with one new drug to 78.7% on three new drugs. 2 years after reaching undetectable concentrations, an estimated 20.1% of treatment-naive patients and 35.7-40.1% of pretreated patients had viral rebound. At 30 months, an estimated 6.6% (95% CI 4.6-8.6) of patients who had maintained undetectable concentrations, 9.0% (5.5-12.5) who had viral rebound, and 20.1% (15.3-24.9) who had never reached undetectable concentrations developed AIDS or died. Compared with patients who maintained undetectable viral load, the adjusted relative hazard of AIDS or death was 1.00 (0.66-1.55) for patients with viral rebound, and 2.40 (1.72-3.33) for patients who failed to reach undetectable concentrations. INTERPRETATION: The rate of virological failure of HAART was high among these patients, but the probability of clinical progression was low even in patients with viral rebound.
Mots-clé
Adult
Aged
Aged, 80 and over
Anti-HIV Agents/administration & dosage/*therapeutic use
CD4 Lymphocyte Count/drug effects
Disease Transmission, Horizontal
Drug Therapy, Combination
Female
HIV Infections/*drug therapy/transmission
*HIV-1/isolation & purification
Humans
Life Tables
Male
Middle Aged
Probability
Prospective Studies
RNA, Viral/isolation & purification
Switzerland
Treatment Failure
Viral Load
Pubmed
Web of science
Création de la notice
25/01/2008 18:07
Dernière modification de la notice
20/08/2019 16:58